inclusion criteria: 1. admitted to a hospital with symptoms suggestive of covid-19. 2. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures. 3. subject (or legally authorized representative) understands and agrees to comply with planned study procedures. 4. male or non-pregnant female adult \> / = 18 years of age at time of enrollment. 5. has laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay in any respiratory specimen or saliva, as documented by either of the following: * pcr or other assay positive in sample collected \< 72 hours prior to randomization; or * pcr or other assay positive in sample collected \>/= 72 hours but \< 7 days prior to randomization and progressive disease suggestive of ongoing sars-cov-2 infection. note: if written documentation of the positive test result is not available at enrollment (e.g., report from other institution), the subject may be enrolled but the pcr should be repeated at the time of enrollment. 6. illness of any duration, and at least one of the following: * radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or * spo2 \< / = 94% on room air, or * requiring supplemental oxygen. 7. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 29. 8. agrees to not participate in another clinical trial (both pharmacologic and other types of interventions) for the treatment of covid-19 through day 29.

inclusion criteria: 1. admitted to a hospital with symptoms suggestive of covid-19. 2. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures. 3. subject (or legally authorized representative) understands and agrees to comply with planned study procedures. 4. male or non-pregnant female adult \> / = 18 years of age at time of enrollment. 5. has laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay in any respiratory specimen or saliva, as documented by either of the following: * pcr or other assay positive in sample collected \< 72 hours prior to randomization; or * pcr or other assay positive in sample collected \>/= 72 hours but \< 7 days prior to randomization and progressive disease suggestive of ongoing sars-cov-2 infection. note: if written documentation of the positive test result is not available at enrollment (e.g., report from other institution), the subject may be enrolled but the pcr should be repeated at the time of enrollment. 6. illness of any duration, and at least one of the following: * radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or * spo2 \< / = 94% on room air, or * requiring supplemental oxygen. 7. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 29. 8. agrees to not participate in another clinical trial (both pharmacologic and other types of interventions) for the treatment of covid-19 through day 29.

inclusion criteria: admitted to a hospital with symptoms suggestive of covid-19. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures. subject (or legally authorized representative) understands and agrees to comply with planned study procedures. male or non-pregnant female adult > / = 18 years of age at time of enrollment. has laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay in any respiratory specimen or saliva, as documented by either of the following: pcr or other assay positive in sample collected < 72 hours prior to randomization; or pcr or other assay positive in sample collected >/= 72 hours but < 7 days prior to randomization and progressive disease suggestive of ongoing sars-cov-2 infection. note: if written documentation of the positive test result is not available at enrollment (e.g., report from other institution), the subject may be enrolled but the pcr should be repeated at the time of enrollment. illness of any duration, and at least one of the following: radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or spo2 < / = 94% on room air, or requiring supplemental oxygen. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 29. agrees to not participate in another clinical trial (both pharmacologic and other types of interventions) for the treatment of covid-19 through day 29.

inclusion criteria: admitted to a hospital with symptoms suggestive of covid-19. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures. subject (or legally authorized representative) understands and agrees to comply with planned study procedures. male or non-pregnant female adult > / = 18 years of age at time of enrollment. has laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay in any respiratory specimen or saliva, as documented by either of the following: pcr or other assay positive in sample collected < 72 hours prior to randomization; or pcr or other assay positive in sample collected >/= 72 hours but < 7 days prior to randomization and progressive disease suggestive of ongoing sars-cov-2 infection. note: if written documentation of the positive test result is not available at enrollment (e.g., report from other institution), the subject may be enrolled but the pcr should be repeated at the time of enrollment. illness of any duration, and at least one of the following: radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or spo2 < / = 94% on room air, or requiring supplemental oxygen. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 29. agrees to not participate in another clinical trial (both pharmacologic and other types of interventions) for the treatment of covid-19 through day 29.

inclusion criteria: 1. admitted to a hospital with symptoms suggestive of covid-19. 2. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures. 3. subject (or legally authorized representative) understands and agrees to comply with planned study procedures. 4. male or non-pregnant female adult > / = 18 years of age at time of enrollment. 5. has laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay in any respiratory specimen or saliva, as documented by either of the following: - pcr or other assay positive in sample collected < 72 hours prior to randomization; or - pcr or other assay positive in sample collected >/= 72 hours but < 7 days prior to randomization and progressive disease suggestive of ongoing sars-cov-2 infection. note: if written documentation of the positive test result is not available at enrollment (e.g., report from other institution), the subject may be enrolled but the pcr should be repeated at the time of enrollment. 6. illness of any duration, and at least one of the following: - radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or - spo2 < / = 94% on room air, or - requiring supplemental oxygen. 7. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 29. 8. agrees to not participate in another clinical trial (both pharmacologic and other types of interventions) for the treatment of covid-19 through day 29.

inclusion criteria: 1. admitted to a hospital with symptoms suggestive of covid-19. 2. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures. 3. subject (or legally authorized representative) understands and agrees to comply with planned study procedures. 4. male or non-pregnant female adult > / = 18 years of age at time of enrollment. 5. has laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay in any respiratory specimen or saliva, as documented by either of the following: - pcr or other assay positive in sample collected < 72 hours prior to randomization; or - pcr or other assay positive in sample collected >/= 72 hours but < 7 days prior to randomization and progressive disease suggestive of ongoing sars-cov-2 infection. note: if written documentation of the positive test result is not available at enrollment (e.g., report from other institution), the subject may be enrolled but the pcr should be repeated at the time of enrollment. 6. illness of any duration, and at least one of the following: - radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or - spo2 < / = 94% on room air, or - requiring supplemental oxygen. 7. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 29. 8. agrees to not participate in another clinical trial (both pharmacologic and other types of interventions) for the treatment of covid-19 through day 29.

inclusion criteria: 1. admitted to a hospital with symptoms suggestive of covid-19. 2. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures. 3. subject (or legally authorized representative) understands and agrees to comply with planned study procedures. 4. male or non-pregnant female adult > / = 18 years of age at time of enrollment. 5. has laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay in any respiratory specimen, as documented by either of the following: - pcr or other assay positive in sample collected < 72 hours prior to randomization; or - pcr or other assay positive in sample collected >/= 72 hours but < 7 days prior to randomization and progressive disease suggestive of ongoing sars-cov-2 infection. note: if written documentation of the positive test result is not available at enrollment (e.g., report from other institution), the subject may be enrolled but the pcr should be repeated at the time of enrollment. 6. illness of any duration, and at least one of the following: - radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or - spo2 < / = 94% on room air, or - requiring supplemental oxygen, or - requiring mechanical ventilation. 7. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 29. 8. agrees to not participate in another clinical trial (both pharmacologic and other types of interventions) for the treatment of covid-19 through day 29.

inclusion criteria: 1. admitted to a hospital with symptoms suggestive of covid-19. 2. subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures. 3. subject (or legally authorized representative) understands and agrees to comply with planned study procedures. 4. male or non-pregnant female adult > / = 18 years of age at time of enrollment. 5. has laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay in any respiratory specimen, as documented by either of the following: - pcr or other assay positive in sample collected < 72 hours prior to randomization; or - pcr or other assay positive in sample collected >/= 72 hours but < 7 days prior to randomization and progressive disease suggestive of ongoing sars-cov-2 infection. note: if written documentation of the positive test result is not available at enrollment (e.g., report from other institution), the subject may be enrolled but the pcr should be repeated at the time of enrollment. 6. illness of any duration, and at least one of the following: - radiographic infiltrates by imaging (chest x-ray, ct scan, etc.), or - spo2 < / = 94% on room air, or - requiring supplemental oxygen, or - requiring mechanical ventilation. 7. women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through day 29. 8. agrees to not participate in another clinical trial (both pharmacologic and other types of interventions) for the treatment of covid-19 through day 29.